MARKET

IRLAF

IRLAF

Irlab Therapeutics AB
Grey
--
NaN%
Opening
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
No Data
About IRLAF
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Webull offers IRLAB Therapeutics AB stock information, including Grey: IRLAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRLAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRLAF stock methods without spending real money on the virtual paper trading platform.